Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.” FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.
Structure Therapeutics (GPCR) Director Russell Angus C. received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 42,833 share options with the following key terms:
- Exercise price: $7.37 per share, based on fair market value of Ordinary Shares
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS (American Depositary Share) represents 3 Ordinary Shares
This equity compensation grant aligns with standard director compensation practices and demonstrates long-term commitment to the company. The 10-year exercise window provides significant time value for the options.
Structure Therapeutics (GPCR) director Ted W. Love received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options with the following key terms:
- Exercise price: $7.37 per share, based on ADS trading price
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
The options convert to ordinary shares, with each ADS representing three ordinary shares. This grant aligns the director's interests with shareholders through long-term equity compensation. The transaction was reported via Form 4 filing within the required timeframe, with signature by attorney-in-fact Jun Yoon on June 25, 2025.
Structure Therapeutics (GPCR) Director Joanne Waldstreicher received a stock option grant on June 23, 2025, representing a significant insider transaction. The grant consists of 51,804 share options with the following key terms:
- Exercise price: $7.37 per share, based on ADS trading price
- Vesting schedule: Equal monthly installments over 12 months from June 23, 2025
- Full vesting: Prior to 2026 annual shareholder meeting
- Expiration date: June 22, 2035
- Each ADS represents 3 ordinary shares
This equity compensation grant aligns the director's interests with shareholders and provides long-term incentive through a 10-year exercise window. The vesting schedule ensures continued engagement through the next annual meeting cycle.